Literature DB >> 23020229

Smoking, von Willebrand factor and ADAMTS-13 in healthy males.

Anwar M Al-Awadhi1, Mehrez M Jadaon, Faisal A Alsayegh, Seham K Al-Sharrah.   

Abstract

While von Willebrand factor (vWF) has been reported to be elevated in smokers, there are no reports on the effects of smoking on its cleaving protease ADAMTS-13, particularly in subjects of Arab ethnicity. This study was conducted to determine the effects of smoking on vWF and ADAMTS-13 antigen and activity levels in Arab males. Venous blood samples from 80 smoking (at rest) and 80 non-smoking healthy males were collected after asking subjects to fast and refrain from smoking for 8 hours. Similar sampling was done for 40 smokers (acute smokers), who were asked to smoke one cigarette immediately before blood collection. Plasma was used to measure ADAMTS-13 antigen and activity levels, as well as vWF antigen and collagen binding activity levels using commercial ELISA kits. Compared to non-smokers, ADAMTS-13 and vWF activities were significantly lower in smokers at rest (p < 0.05). Acute smokers had significantly higher levels of vWF activity and ADAMTS-13 antigen and activity levels (p < 0.01), compared to smokers at rest. Our results suggest that high vWF activity is accompanied by an increase in ADAMTS-13 activity as a natural physiological mechanism to degrade the elevated vWF molecules. If not followed by a subsequent smoke, the activities of both proteins subside. It is possible that the repeated increase in vWF and constant degradation by ADAMTS-13 results in lower overall levels of both proteins in smokers (at rest) compared to nonsmokers who do not experience a similar (repeated) injury to the endothelium.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23020229     DOI: 10.3109/00365513.2012.725864

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  4 in total

1.  Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels.

Authors:  Qianyi Ma; Paula M Jacobi; Brian T Emmer; Colin A Kretz; Ayse Bilge Ozel; Beth McGee; Chava Kimchi-Sarfaty; David Ginsburg; Jun Z Li; Karl C Desch
Journal:  Blood Adv       Date:  2017-06-19

2.  Association of the von Willebrand Factor-ADAMTS13 Ratio With Incident Cardiovascular Events in Patients With Peripheral Arterial Disease.

Authors:  David Green; Lu Tian; Philip Greenland; Kiang Liu; Melina Kibbe; Russell Tracy; Sanjiv Shah; John T Wilkins; Mark D Huffman; Yihua Liao; Donald Lloyd Jones; Mary M McDermott
Journal:  Clin Appl Thromb Hemost       Date:  2016-06-17       Impact factor: 2.389

3.  Association between plasma ADAMTS-7 levels and severity of disease in patients with stable obstructive coronary artery disease.

Authors:  Jie Yu; Boda Zhou; Haiyi Yu; Jiangli Han; Ming Cui; Fuchun Zhang; Guisong Wang; Lijun Guo; Wei Gao
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

4.  Evaluation of von Willebrand factor in COPD patients.

Authors:  Thiago Prudente Bártholo; Cláudia Henrique da Costa; Rogério Rufino
Journal:  J Bras Pneumol       Date:  2014 Jul-Aug       Impact factor: 2.624

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.